Christopher Kurtz

Christopher Kurtz brings more than 27 years of combined experience in development, scale-up and commercialization of pharmaceuticals, including sterile products and devices in the U.S. and global arenas. Mr. Kurtz has successfully established supply capabilities and navigated numerous products from late-stage development through approval, launch and sustained commercialization.

Prior to joining Eiger, Mr. Kurtz served as Executive Vice President of Technical Operations at Cidara Therapeutics where he established and validated the supply chain for a novel antifungal agent, as well as advancing a pan-genotypic biologic flu prophylactic into first in human studies. Prior to Cidara, Mr. Kurtz served as Head of Commercial API Manufacturing at Gilead Sciences, where he and his team played an instrumental role in the launch and ongoing production of products such as Descovy, Biktarvy and Veklury (remdesivir). Mr. Kurtz previously served as Vice President of Drug Device Industrialization at AbbVie, where he led product scale-up and industrialization projects for drug-device combinations. Prior to that, Mr. Kurtz held a number of leadership positions where managed the development, scale-up and commercialization of drugs, biologics, medical devices and combination products at various companies, including Monsanto, Nektar Therapeutics, Alza Corporation, Alexza and Novo Nordisk.

Mr. Kurtz holds a B.S. in Chemical Engineering from the University of Colorado and is a graduate of the Westinghouse S3G Nuclear Engineering Program. He was a member of the United States Navy, serving in the Submarine Force, where he was a graduate of the Naval Nuclear Propulsion School.